Jose E. Lallana-Meca
Cartagena, MU, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 119 publications
Biological and clinical stability after switching from intravenous to subcutaneous natalizumab in RRMS under standard and extended dosing.
Journal: Frontiers in immunology
Published: May 12, 2026
Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: April 28, 2026
Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.
Journal: International journal of molecular sciences
Published: April 15, 2026
Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.
Journal: Brain : a journal of neurology
Published: March 12, 2026
XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part II)
Journal: Revista de neurologia
Published: March 10, 2026
XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part I)
Journal: Revista de neurologia
Published: March 10, 2026
Educational programs based on healthy habits to improve quality of life and psychosocial profile in women with multiple sclerosis: The ADVICE protocol study.
Journal: Contemporary clinical trials
Published: January 28, 2026
Educational programs based on healthy habits to improve quality of life and psychosocial profile in women with multiple sclerosis: The ADVICE protocol study.
Journal: Contemporary clinical trials
Published: January 28, 2026
Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.
Journal: Therapeutic advances in neurological disorders
Published: January 14, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: January 13, 2026
Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study.
Journal: Therapeutic advances in neurological disorders
Published: January 09, 2026
Last Updated: 09/26/2026